Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $278,100.00 in Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the sale, the chairman now owns 651,291 shares of the company’s stock, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Poseida Therapeutics Stock Down 0.5 %

Shares of NASDAQ PSTX traded down $0.05 during trading hours on Wednesday, hitting $9.33. The stock had a trading volume of 3,346,633 shares, compared to its average volume of 699,993. The firm’s 50-day moving average price is $3.02 and its two-hundred day moving average price is $3.01. Poseida Therapeutics, Inc. has a 52 week low of $1.87 and a 52 week high of $9.42. The company has a market capitalization of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20.

Institutional Trading of Poseida Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after acquiring an additional 473,746 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock worth $2,648,000 after purchasing an additional 391,801 shares during the last quarter. Renaissance Technologies LLC boosted its position in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Poseida Therapeutics by 62.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after purchasing an additional 138,510 shares during the last quarter. Finally, Blair William & Co. IL raised its position in shares of Poseida Therapeutics by 14.1% in the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock valued at $3,216,000 after purchasing an additional 136,273 shares during the period. 46.87% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on PSTX. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reissued a “neutral” rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.50.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.